Cellectis (CLLS) EBITDA Margin (2015 - 2026)
Cellectis (CLLS) posted EBITDA Margin of 435.64% for Q1 2026, down 219.25% on a QoQ basis from 136.46% in Q4 2025, and down 30257.0% year-over-year from N/an in Q1 2025.
Cellectis (CLLS) has 12 years of EBITDA Margin data on file, last reported at 435.64% in Q1 2026.
- In Q1 2026, EBITDA Margin fell 30257.0% year-over-year to 435.64%; the TTM figure through Mar 2026 stood at 62.6% (up 3287.0% YoY), while the FY2025 annual figure was 81.64%, up 3937.0% from the prior year.
- EBITDA Margin slipped to 435.64% in Q1 2026, from 136.46% in the prior quarter.
- Across five years, EBITDA Margin topped out at 22.86% in Q3 2025 and bottomed at 16856.83% in Q1 2023.
- A 5-year average of 4408.53% and a median of 435.64% in 2026 frame the typical range for EBITDA Margin.
- Annual changes were most pronounced in 2022 — EBITDA Margin slumped 1512056 bps — and 2024, when it jumped 1639539 bps.
- Year by year, EBITDA Margin stood at 21.09% in 2022, then plunged by 49450 bps to 10451.94% in 2023, then soared by 99 bps to 52.28% in 2024, then plunged by 161 bps to 136.46% in 2025, then slumped by 219 bps to 435.64% in 2026.
- The last three EBITDA Margin figures came in at 435.64% (Q1 2026), 136.46% (Q4 2025), and 22.86% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -6.43% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 38.10% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 18.35% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 17.24% |
| 10 | Cellectis | 20.83 Bn | 20.62 Bn | - | -435.64% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -435.64% |
| Dec 31, 2025 | -136.46% |
| Sep 30, 2025 | 22.86% |
| Jun 30, 2025 | -57.32% |
| Mar 31, 2025 | -133.07% |
| Dec 31, 2024 | -52.28% |
| Sep 30, 2024 | -66.48% |
| Jun 30, 2024 | -213.51% |
| Mar 31, 2024 | -461.44% |
| Dec 31, 2023 | -10,451.94% |
| Sep 30, 2023 | -13,336.13% |
| Jun 30, 2023 | -13,270.22% |
| Mar 31, 2023 | -16,856.83% |
| Dec 31, 2022 | -21.09% |
| Sep 30, 2022 | -15,630.29% |
| Jun 30, 2022 | -2,089.75% |
| Mar 31, 2022 | -1,755.44% |
| Dec 31, 2021 | -74.80% |
| Sep 30, 2021 | -509.72% |
| Jun 30, 2021 | -335.37% |
| Mar 31, 2021 | -77.76% |
| Dec 31, 2020 | -286.94% |
| Sep 30, 2020 | -475.04% |
| Jun 30, 2020 | -1,139.00% |
| Mar 31, 2020 | 28.75% |
| Dec 31, 2019 | -870.34% |
| Sep 30, 2019 | -314.02% |
| Jun 30, 2019 | -3,049.13% |
| Mar 31, 2019 | -2,231.56% |
| Dec 31, 2018 | -3,023.24% |
| Sep 30, 2018 | -3,190.29% |
| Jun 30, 2018 | -429.71% |
| Mar 31, 2018 | -412.28% |
| Dec 31, 2017 | -401.77% |
| Sep 30, 2017 | -419.85% |
| Jun 30, 2017 | -305.45% |
| Mar 31, 2017 | -293.25% |
| Dec 31, 2016 | -247.87% |
| Sep 30, 2016 | -114.48% |
| Jun 30, 2016 | -1,678.06% |
| Mar 31, 2016 | -292.48% |
| Dec 31, 2015 | 3.65% |
| Sep 30, 2015 | -176.93% |
| Jun 30, 2015 | -165.47% |
| Mar 31, 2015 | -42.22% |